Repare Therapeutics’ Post

Steve Reed, a 77-year-old living with metastatic prostate cancer since 1998, faced significant challenges with chemotherapy. After 18 cycles, the side effects became unbearable. In January 2023, his oncologist suggested a new theranostic drug, Pluvicto (177Lu-PSMA-617). This treatment targets cancer cells with minimal side effects, offering Reed a better quality of life. Since starting Pluvicto, he experienced virtually no side effects and resumed activities he loves, including travel. Theranostics is revolutionizing cancer treatment, providing new hope for patients with advanced stages of the disease. #CancerTreatment #Theranostics #Pluvicto #MedicalInnovation #Oncology https://lnkd.in/efiKbxgJ

This inspiring story about the promising advancements in cancer treatment with theranostics highlights how innovative therapies can improve quality of life for those with advanced cancer. This is a must-read for anyone interested in the future of oncology and medical innovation. Check out the full story! #CancerTreatment #MedicalInnovation #Oncology #Theranostics

In this interview with OncLive, Dr. Michelina Cairo of Texas Oncology discusses the adverse effect profiles of two different therapies for patients with HER2-positive metastatic breast cancer: https://lnkd.in/ghaQfuc6 #BreastCancer #HER2 #MetastaticBreastCancer

The quest for a novel target for pancreatic cancer has become an urgent imperative due to the exceptionally challenging nature of this disease. Pancreatic cancer is notorious for its aggressive behavior, late-stage diagnosis, and limited treatment options. Its five-year survival rate remains alarmingly low, and the existing therapies often offer only modest benefits. Thus, identifying a fresh and more precise therapeutic target is crucial to revolutionize the treatment landscape. Such a breakthrough could potentially lead to more effective, less toxic treatments, earlier detection methods, and improved patient outcomes. Pancreatic cancer, in its current state, demands innovative approaches, and the pursuit of a novel target is a pressing necessity in the relentless battle against this deadly malignancy. Read our latest blog in this topic and do share your opinions.

In this month of Pink October, we found important to take a look of the situation of breast cancer. We summed up advances in healthcare and oncology in a Candriam paper. #candriam #investing4tomorrow

I want to share this great article in Nature by the team at the leading French oncology research center, Gustave Roussy, about why and how we urgently need to reframe the way we see, treat and pay for cancer care, because cancer is a cell problem, not an organ problem. We continue to live in outdated paradigms that prevent us from being more effective in treating and caring for patients. We may all suffer from cancer at some point... Build knowledge. https://lnkd.in/dmizGQWq

Expert Discussion on #AntibodyDrugConjugates in HER2+/- Breast Cancer 👇 Targeted Oncology discusses the current landscape of antibody-drug conjugates for breast cancer subtypes beyond HER2-positive disease. Click the link below to read the article 🔗 https://lnkd.in/gWa_nhYt

Knowledge is power, especially when it comes to empowering patients undergoing cancer treatment. Researchers found that informing CRC patients about their ctDNA testing results lessened their anxiety about their cancer recurring. Learn more about this study, which will be presented at the 2024 ASCO Gastrointestinal Cancers Symposium, here: #cancerresearch #oncology

GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer

🚨 Exciting news alert! 🚨 The groundbreaking trial of a new bowel cancer drug has shown incredible results, shrinking 60% of tumors. This is a huge leap forward in the fight against cancer. Check out the full article in The Sun to learn more about this game-changing development. #CancerResearch #MedicalInnovation #HealthBreakthroughs https://ift.tt/5C0VaqE